Nikol Dimova

A new hybrid molecule, combining the pharmacologically relevant scaffolds of valproic acid and trimetazidine, is reported. The target compound was synthesized via a rapid mechanochemical approach using a planetary ball mill, enabling the efficient coupling of the branched-chain valproic acid moiety with the piperazine fragment of trimetazidine. The structure of the new compound was fully characterized by ¹H and ¹³C NMR spectroscopy, IR spectroscopy, and high-resolution mass spectrometry, confirming its identity. This work demonstrates the applicability of mechanosynthesis as a straightforward and sustainable strategy for the preparation of novel hybrid molecules of potential pharmacological interest.

In this Short Note type article, we report the synthesis of a new hybrid molecule, N-(3,4-dimethoxyphenethyl)-2-propylpentanamide, using a solvent-minimized mechanochemical method that provides a simple and efficient synthetic approach. The process achieved high yield. The compound was confirmed by melting-point analysis, ¹H and ¹³C NMR, IR spectroscopy, and mass spectrometry.

Background: Trimetazidine is a clinically established cardioprotective agent with anti-ischemic and antioxidant properties, widely used in the management of coronary artery disease. Combining its metabolic and cytoprotective effects with the potent anti-inflammatory activity of profens presents a promising therapeutic strategy. Methods: Five novel trimetazidine–profen hybrid compounds were synthesized using N,N′-dicyclohexylcarbodiimide-mediated coupling and structurally characterized by NMR and high-resolution mass spectrometry. Their antioxidant activity was evaluated by hydroxyl radical scavenging assays (HRSA), and the anti-inflammatory potential was assessed via the inhibition of albumin denaturation (IAD). Lipophilicity was determined chromatographically. Molecular docking and 100 ns molecular dynamics simulations were performed to investigate the binding modes and stability in human serum albumin (HSA) binding sites. The acute toxicity of the hybrid molecules was predicted in silico using GUSAR software. Results: All synthesized hybrids demonstrated varying degrees of biological activity, with compound 3c exhibiting the most potent antioxidant (HRSA IC₅₀ = 71.13 µg/mL) and anti-inflammatory (IAD IC₅₀ = 108.58 µg/mL) effects. Lipophilicity assays indicated moderate membrane permeability, with compounds 3c and 3d showing favorable profiles. Docking studies revealed stronger binding affinities of S-enantiomers, particularly 3c and 3d, to Sudlow sites II and III in HSA. Molecular dynamics simulations confirmed stable ligand–protein complexes, highlighting compound 3c as maintaining consistent and robust interactions. The toxicity results indicate that most hybrids, particularly compounds 3b–3d, exhibit a favorable safety profile compared to the parent trimetazidine. Conclusion: The hybrid trimetazidine–profen compounds synthesized herein, especially compound 3c, demonstrate promising dual antioxidant and anti-inflammatory therapeutic potential. Their stable interaction with serum albumin and balanced physicochemical properties support further development as novel agents for managing ischemic heart disease and associated inflammatory conditions.